Corbus Pharmaceuticals Holdings (CRBP) announced Monday morning that its Phase 2 study of Resunab, for the treatment of diffuse cutaneous systemic sclerosis, demonstrated a medically meaningful improvement over placebo.
from RTT - Before the Bell http://ift.tt/2fVa4Zk
via IFTTT
No comments:
Post a Comment